138 related articles for article (PubMed ID: 16651648)
1. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
2. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
Wong M; Evans S; Rivory LP; Hoskins JM; Mann GJ; Farlow D; Clarke CL; Balleine RL; Gurney H
Clin Pharmacol Ther; 2005 Jan; 77(1):33-42. PubMed ID: 15637529
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone as a probe for vinorelbine clearance.
Puisset F; Dalenc F; Chatelut E; Cresteil T; Lochon I; Tisnes P; Roché H
Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
[TBL] [Abstract][Full Text] [Related]
4. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
Schott AF; Rae JM; Griffith KA; Hayes DF; Sterns V; Baker LH
Cancer Chemother Pharmacol; 2006 Jul; 58(1):129-35. PubMed ID: 16283312
[TBL] [Abstract][Full Text] [Related]
5. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
[TBL] [Abstract][Full Text] [Related]
6. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
7. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
10. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
11. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.
Briasoulis E; Pappas P; Puozzo C; Tolis C; Fountzilas G; Dafni U; Marselos M; Pavlidis N
Clin Cancer Res; 2009 Oct; 15(20):6454-61. PubMed ID: 19808873
[TBL] [Abstract][Full Text] [Related]
12. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
[TBL] [Abstract][Full Text] [Related]
13. Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?
Baker SD; Sparreboom A
J Clin Oncol; 2006 Jun; 24(16):2412-3. PubMed ID: 16651645
[No Abstract] [Full Text] [Related]
14. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
[TBL] [Abstract][Full Text] [Related]
15. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN
Acta Oncol; 2007; 46(3):361-6. PubMed ID: 17450472
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
18. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
[TBL] [Abstract][Full Text] [Related]
20. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]